Cellectis announced a major strategic pivot, shifting its focus from allogeneic CAR T-cell therapies to in vivo gene editing for chronic diseases. This significant change in direction, including exiting existing development programs, led to a substantial stock price decline.
Cellectis is undergoing a significant strategic overhaul, abandoning its allogeneic CAR T-cell programs (lasme-cel and eti-cel) to focus entirely on in vivo gene editing. This decision is driven by shifting market dynamics, increased competition, and lower relapse rates in frontline treatments for their previous focus areas. While this extends their cash runway into H2 2028, the immediate market reaction was a sharp 27% decline, indicating investor skepticism or disappointment with the change and the exit from previously promising assets. For traders, this represents a high-risk, high-reward scenario: short-term negative sentiment due to the pivot and asset abandonment, but a long-term opportunity if their new in vivo gene editing pipeline (HEAL-101 and HEAL-201) proves successful in clinical trials, with preliminary data expected in 2027-2028.